Does Rallies show 13F holders for SRPT?

Yes. Rallies tracks hedge fund and 13F ownership data for SRPT, including fund names, share counts, latest tracked quarter, and position changes when available.

Is SRPT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SRPT. It does not provide personalized investment advice.

SRPT (Sarepta Therapeutics) Stock Analysis - Hedge Fund Holdings

Sarepta Therapeutics (SRPT) is a publicly traded Healthcare sector company. As of May 21, 2026, SRPT trades at $17.07 with a market cap of $1.80B and a P/E ratio of 23.37. SRPT moved +2.88% today. Year to date, SRPT is -18.75%; over the trailing twelve months it is -57.19%. Its 52-week range spans $10.42 to $138.81. Analyst consensus is neutral with an average price target of $21.64. Rallies surfaces SRPT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns SRPT stock?

Hedge funds tracked by Rallies that own SRPT include Orbimed Advisors, Soros Fund, Bridgewater Associates, Pinebridge Investments, and Centerbook Partners. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Sarepta Therapeutics.

SRPT Key Metrics

Key financial metrics for SRPT
Metric	Value
Price	$17.07
Market Cap	$1.80B
P/E Ratio	23.37
EPS	$0.73
Dividend Yield	0.00%
52-Week High	$138.81
52-Week Low	$10.42
Volume	3.86K
Avg Volume	0
Revenue (TTM)	$2.18B
Net Income	$65.06M
Gross Margin	0.00%

Top Hedge Funds Holding SRPT

Orbimed Advisors holds 963.40K shares of SRPT, changed +0.93% as of Dec 31, 2024.
Soros Fund holds 230.89K shares of SRPT, changed +11.77% as of Dec 31, 2024.
Bridgewater Associates holds 134.28K shares of SRPT, changed -52.14% as of Mar 31, 2026.
Pinebridge Investments holds 9.52K shares of SRPT, changed -62.12% as of Mar 31, 2025.
Centerbook Partners holds 4.40K shares of SRPT, changed +0.00% as of Mar 31, 2025.

Latest SRPT News

Sarepta Therapeutics Posts $331M Q1 Profit, $730.8M Revenue Beat But Elevidys Demand Slumps — May 6, 2026
Sarepta Shows Dose-Dependent Muscle Uptake and Biomarker Effects in FSHD1, DM1 Trials — Mar 25, 2026
Sarepta Therapeutics Shares Jump 4.31% After FDA Biologics Chief Resignation — Mar 9, 2026
FDA Biologics Chief to Depart After Blocking Sarepta’s Elevidys Approval — Mar 9, 2026
Wells Fargo Cuts Sarepta PT to $38, Baird Lowers Target to $20 — Mar 1, 2026

Recent SRPT Insider Trades

Mayo Stephen sold 7.24K (~$123.21K) on Mar 12, 2026.
Estepan Ian Michael sold 13.19K (~$294.20K) on Dec 16, 2025.
Nicaise Claude sold 2.49K (~$248.20K) on Mar 12, 2025.

SRPT Analyst Consensus

24 analysts cover SRPT: 0 strong buy, 6 buy, 13 hold, 5 sell, 0 strong sell. Consensus rating is neutral. Average price target: $21.64.

Common questions about SRPT

Who owns SRPT stock?: Hedge funds tracked by Rallies that own SRPT include Orbimed Advisors, Soros Fund, Bridgewater Associates, Pinebridge Investments, and Centerbook Partners. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Sarepta Therapeutics.
Does Rallies show 13F holders for SRPT?: Yes. Rallies tracks hedge fund and 13F ownership data for SRPT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is SRPT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SRPT. It does not provide personalized investment advice.